• About Lareb
    About Lareb
  • Search information about ADRs
    Search information about ADRs
  • Subscribe to newsletter
    Subscribe to newsletter

Updates RSS icon

  • Guillain-Barré Syndrome after COVID-19 vaccination
    Until October 12th 2022, the Netherlands Pharmacovigilance Centre Lareb received 72 reports of  Guillain-Barré Syndrome (GBS) following COVID-19 vaccination. GBS is labeled as a ra ...
    Read more
    10 MAR
  • Propylthiouracil and ANCA vasculitis
    The Netherlands Pharmacovigilance Centre Lareb received seven well-documented reports on propylthiouracil and anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis. Prop ...
    Read more
    15 FEB
  • Call for abstracts for the ISoP Mid-Year Symposium 2023
    This year the ISoP mid-year meeting will be hosted by the Netherlands Pharmacovigilance Centre Lareb on 1-2 June 2023 in Leiden, the Netherlands. This meeting will focus on connect ...
    Read more
    13 FEB
  • Higher probability of experiencing a side effect in women after COVID-19 vaccination
    Females have a two-fold higher odds of experiencing an adverse event following immunization (AEFI) than males after a COVID-19 vaccination. This difference was greater after the fi ...
    Read more
    07 FEB
  • Triage individual case safety reports using prediction model
    The number of Individual Case Safety Reports (ICSRs) in pharmacovigilance databases are rapidly increasing world-wide. New methods are required to support scientific assessors in   ...
    Read more
    13 DEC
  • Side effects of Tea Tree Oil
    The World Health Organization (WHO) received 159 reports of complaints associated with the use of  tea tree oil products. Skin complaints such as rash, hypersensitivity and redness ...
    Read more
    08 DEC